Semaglutide may relieve peripheral arterial disease experienced by many patients with type 2 diabetes, a new Montreal study ...

A new international study has found that semaglutide, a medication commonly used to treat type 2 diabetes and obesity, ...

Semaglutide improved maximum walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease.

After 52 weeks of treatment, patients receiving semaglutide experienced a 21% improvement in maximum walking distance compared to just 8% in the placebo group. "The study found a significant ...

Join our Peer Health Educator (PHE) volunteers for weekly beginner/intermediate runs during the fall and/or winter terms if you want to start running, increase your distance, improve your time, and/or ...

Novo Nordisk announced results of the Phase IIIb STRIDE trial of semaglutide’s impact on walking capacity in people with PAD and T2D.

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL trial finds Rybelsus lowers cardiovascular risk by 14%.

The double-blind, randomised, placebo-controlled STRIDE trial achieved its primary endpoint, with semaglutide 1.0 mg demonstrating a superior and clinically meaningful improvement of 13% in maximum ...

Additionally, the trial met all secondary endpoints, demonstrating significant improvement with semaglutide vs placebo in pain-free walking distance (ETR: 1.11 [95% CI, 1.03-1.20; P =.0046 ...